Key points
Identifies lipid dysregulation as a shared metabolic sub-pathway in two ALS cohorts. Researchers are hopeful that this result could lead to a more targeted lipidomic research for new insight in ALS pathogenesis and possible treatments.
Affiliates
Stephen A Goutman [1][2], Kai Guo [1][2], Masha G Savelieff [2], Adam Patterson [1][2], Stacey A Sakowski [1][2], Hani Habra [3], Alla Karnovsky [3], Junguk Hur [4], Eva L Feldman [1][2]
- Department of Neurology, University of Michigan, Ann Arbor, MI, USA.
- NeuroNetwork for Emerging Therapies, University of Michigan, Ann Arbor, MI, USA.
- Department of Computational Medicine & Bioinformatics, University of Michigan, Ann Arbor, MI, USA.
- Department of Biomedical Sciences, University of North Dakota, Grand Forks, ND, USA.
Summary
This paper a study by the University of Michigan to study ALS pathogenesis through the use of metabolomics. Metabolomics were performed on two ALS cohorts and two control cohorts. The study found shared metabolic sub-pathways in both ALS cohort centered around lipid dysregulation. The researchers are hopeful that the results of this cohort study could point towards more targeted lipidomic research to provide new insights in ALS pathogenesis and possible treatments.